DOCSLIB.ORG

Calcium Dobesilate Versus Micronised Purified Flavonoid Fraction of Diosmin in the Treatment of Chronic Venous Disease: a Randomized Prospective Study

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Calcium Dobesilate Versus Micronised Purified Flavonoid Fraction of Diosmin in the Treatment of Chronic Venous Disease: a Randomized Prospective Study Acta Medica Mediterranea, 2018, 34: 657 CALCIUM DOBESILATE VERSUS MICRONISED PURIFIED FLAVONOID FRACTION OF DIOSMIN IN THE TREATMENT OF CHRONIC VENOUS DISEASE: A RANDOMIZED PROSPECTIVE STUDY EMINE SEYMA DENLI YALVAC1, MURAT DEMIROĞLU2, SIDIKA GURSEL1, EBUZER AYDIN1 ¹Medeniyet University Faculty of Medicine, Department of Cardiovascular Surgery, Istanbul, Turkey - 2Medeniyet University Faculty of Medicine, Department of Department of Orthopedics and Traumatology, Istanbul, Turkey ABSTRACT Introduction: Chronic venous disease (CVD) of the lower extremities has a substantial effect on quality of life. The clinical, etiology, anatomy, pathophysiology classification (CEAP) is a frequently used classification for CVD. Patients with varicose veins are classified as CEAP class C2. Veno-active drugs (VAD) such as Calcium Dobesilate or Micronised Purified Flavonoid Fraction of Diosmin (MPFF) reduce the symptoms of pain associated with CVD. However, although the effectiveness of VAD is well established, it is controversial. The aims of the this study were to compare the efficacy of two VAD (Calcium dobesilate and MPFF in the treat- ment of CVD in view of the intended visual analogue scale (VAS) and duplex scanning (DS) changes such as measuring great saphe- nous vein (GSV) diameter. Materials and methods: A total of 24 patients who had no prior VAD treatment with CEAP class C2, with no family history of CVD were treated; 12 received calcium dobesilate and 12 received MPFF for 60 days. Comorbidities such as hypertension (HT) and diabetes mellitus (DM) were examined. Before and after treatment period, the patients were investigated with DS for diameter of GSV and pain complaint according to VAS were recorded. Results: There were no difference in treatment groups in terms of age, gender, or the comorbidities. For the whole groups, no significant differences were recorded before and after treatment regarding DS parameters. On the other hand, pain was significantly reduced for the group 1 and 2 according to VAS (respectively p=0,04, p=0,03). Conclusion: In this study, pain was reduced in both groups, but no improvement was observed in DS findings. The role of VAD in treatment of patients with CVD needs to be improved in the existing recommendations. Keywords: Chronic venous disease, Veno active drugs, Calcium dobesilate, Micronised purified flavonoid fraction, visual ana- logue scale. DOI: 10.19193/0393-6384_2018_3_101 Received November 30, 2017; Accepted January 20, 2018 Introduction been associated with the development of CVD(2). The strongest known risk factor for CVD is old age Chronic venous disease (CVD) of the lower in both male and female patients(2). extremities caused by venous hypertension is com- Clinical findings show a wide spectrum rang- monly seen in the general population(1).Venous ing from spider veins which is very small vessels hypertension as a result of venous insufficiency can up to leg ulcers. CVD decreases quality of life due damage the vein valves and function.Loss ofthe to the symptoms such as pain, weight, swelling and veinvalve effectiveness is commonly resulted as cramps(1). Pain is usually reduced by walking or by varicose veins(1). 25% to 33% of female and 10% to elevating the legs. Clinical, etiologic, anatomical 20% of male adults suffer from varicose veins(1). and pathophysiological presentations of CVD are Many risk factors such as old age, female gender, described as the CEAP classification in order to family history, obesity and standing profession have provide a common communication and diagnos- 658 Emine Seyma Denli Yalvac, Murat Demiroğlu et Al tics(3). The CEAP classification is divided into 6 The exclusion criteria were as follows: 1. classes according to their clinical findings. These Patient under eighteen years, pregnant or malignan- are CEAP class1 (reticular and spider veins), CEAP cy(2). Patients with CEAP class1, 3, 4, 5, 6; 3. Prior class 2 (simple varicose veins), CEAP class 3 (vari- VAD treatment (4. History of venous thrombosis, cose veins with oedema), CEAP class 4 (skin vein surgery or sclerotherapy.They were random- changes without ulceration), CEAP class C5 ized by closed envelope method into two groups to (healed ulceration), and CEAP class C6 (active receive calcium dobesilate (500 mg peroral twice in ulcers). A duplex scanning (DS) is a noninvasive a day) as group 1 or MPFF (500 mg peroral twice procedure to determine CVD. DS combining B- in a day) as group 2. In patients with bilateral dis- mode and color flow imaging ensure assessment of ease, the leg with worse disease was evaluated in diameter of great saphenous vein (GSV) and under- the study. Patients were questioned for hypertension estimates the degree of venous reflux. Increased (HT) and diabetes mellitus (DM) disease. All the diameter of the GSV is an expected finding in vari- patients were prescribed low pressure(pressure 10- cose veins and larger GSV diameter is thought to 15 mm Hg) compression stockings. indicate more symptomatic patients(4). Veno-active Before and 60 days after VAD treatment, the drugs (VAD) alleviate the symptoms of CVD(5). patients answered the visual analogue scale (VAS) Calcium dobesilate (2,5 dihydroxybenzenesul- from 0 (none/absent) to 5 (severe) for the symp- fonate) is a synthetical drug that has an effect on toms of pain, cramps, heaviness, paresthesia, and CVD by contributing to an oedema-protective feeling of swelling. Twenty-six patients who did not effect(6). Micronized purified flavonoid fraction receive their VAD properly in their follow-up were (MPFF), an oral VAD, consists of 90% micronized excluded from the study. The study continued with diosmin and 10% flavonoids(7). twenty-four patients. The patients underwent DS of It improves venous tone and lymphatic the lower extremities in the upright position (after 4 drainage, and reduces capillary hyperpermeability pm) by the same physician and the diameter of because it protects microcirculation from inflamma- GSV in the symptomatic groin was measured 5 cm tory processes(8). The effectiveness of VAD has been distal to the saphenofemoral junction (SFJ) before reported in many studies.But there are very few and 60 days afterVAD treatment. Data analysis was studies about VAD to prove the effectiveness based performed with the ultrasound general electric logiq on a GSV diameter and a few studies evaluating p5.During the treatment, the patients wore com- these effects by looking at the visual analogue scale pression stockings all day long and removing (VAS) for the symptoms of pain, cramps, heaviness before bed. and paresthesia. The purposes of this randomized, prospective study are to evaluate and to compare Statistical analysis the effectiveness of these two VAD (Calcium dobe- NCSS (Number Cruncher Statistical System) silate and MPFF) on decreasing diameter of the 2007 (Kaysville, Utah, USA) program was used for GSV and VAS due to CVD. statistical analysis. In the comparison of quantita- tive data; Mann Whitney U test was used for two Materials and methods group comparisons of the variables with no normal distribution. Wilcoxon Signed Ranks test was used The hospital ethics committeehas approved for intragroup comparisons. Fisher’s Exact test was this study. All patients were informed about the used for comparison of qualitative data and p<0.05 study and written approval was obtained.This study was regarded significant. included fifty patients referred to our outpatient clinic between October 2016 and March 2017. Results Suffering from CEAP class2 was the main criteria for inclusion of the study. The diagnosis of CEAP Twenty-four patients comprising 15 women class 2 was described visible or palpable varicose (62.5%) and 9 men (37.5%) were enrolled in the veins without oedema with the patient standing. study. The ages ranged from 33 to 68 years with a The others criteria for inclusionwerethe duration of mean age 51,00 ± 11,68 years. There was no statis- the complaints with a minimum of one year and a tically significant difference between groups maximum of two years,no family history of CVD according to age, gender, HT and DM distribu- disease and nosmoking. tions(p>0,05) (Table 1). Calcium dobesilate versus micronised purified flavonoid fraction of diosmin in the treatment of chronic venous disease... 659 Drug groups The pretreatment VAS measure was 3,58±1,08 in group 1 (Table 3). The pretreatment VAS mea- Group 1 (n=12) Group 2 (n=12) (Calcium dobesilate) (MPFF) sure was 3,67±0,98 in group 2 (Table 3). Min-Max (Median) 33-68 (54) 35-68 (44,5) The post-treatment VAS measure was Age (years) 2,17±1,19 in group 1 (Table 3). The post-treatment Mean+Sd 54,33±11,44 47,67±11,41 VAS measure was 58±1,00 in group 2 (Table 3). Female 8 (66,7) 7 (58,3) There was no statistically significant difference Gender n (%) Male 4 (33,3) 5 (41,7) between the pre-treatment and post-treatment VAS measures according to the groups (p> 0,05). The DM n (%) 3 (25,0) 3 (25,0) mean decrease of 1,42 units in post-treatment VAS HT n (%) 8 (66,7) 6 (50,0) measure was statistically significant in group 1 Table1: Evaluation of demographic variables according (p=0,004; p<0,01) (Table 3). The mean decrease of to groups. 2,08 units in post-treatment VAS measure was sta- aMann Whitney U Test bFisher’s Exact Test tistically significant in group 2 (p=0,003; p<0,01) Sd: Standard deviation (Table 3). Both products were well tolerated, with no dif- Drug Groups ference in the adverse event. The pre-treatment VAS Group 1 (n=12) Group 2 (n=12) mean diameter of GSV was 6,31±1,76 cm on the (Calcium dobesilate) (MPFF) symptomatic groin, in group 1 (Table 2). The pre- Min-Max (Median) 2-5 (3,5) 2-5 (3,5) treatment mean diameter of GSV was 6,43±2,07 cm Pre-treatment on the symptomatic groin, in group 2 (Table 2).
Load more

Recommended publications
  • Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
    Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Appendices Feb 2010 Inclusion of Cobalt and 2019 Fei Prohibited
    APPENDIX 2 CLASSIFICATION OF PROHIBITED SUBSTANCES 1. This classification describes the types of Prohibited Substances and places same in specific categories. The list shall be published on the Club’s Notice Board. CLASS I Drugs that have the greatest pharmacological potential to affect the racing performance of a horse and which have no accepted medical use in a racehorse. These include substances which are potent stimulants of the Central Nervous System (CNS). Examples of drugs in this Class include, but are not limited to: Amphetamines, fentanyl, etorphine, cocaine, morphine, meperidine, opiates, opium derivatives, synthetic opiods, psychoactive drugs. CLASS II Drugs that have a high pharmacological potential for affecting the racing performance of a horse. These include: (i) substances which are pharmacologically active in altering the cons (ii) substances which are not generally accepted as therapeutic agents in the racing horse; and (iii) substances, some of which may have legitimate use in equine medicine but should not be found in the racing horse, such as injectable local anaesthetics. 1 Groups of drugs in this Class include, but are not limited to: (a) Opiate partial agonists, or agonistsantagonists; (b) Non-opiate psychotropic drugs, which may have stimulant, depressant, analgesic or neuroleptic effects; (c) Miscellaneous drugs which might have a stimulant effect on the CNS; (d) Drugs with prominent CNS depressant action; (e) Antidepressant and antipsychotic drugs, with or without prominent CNS stimulatory or depressant effects; (f) Muscle blocking drugs which have direct neuromuscular blocking action; (g) Local anaesthetics which have a reasonable potential for use as nerve blocking agents (except procaine); and (h) Snake venom and other biologic substances which may be used as nerve blocking agents.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Rabe E, Ballarini S, Lehr L; Doxium EDX09/01 Study Group
    1: Rabe E, Ballarini S, Lehr L; Doxium EDX09/01 Study Group. A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency. Phlebology. 2015 May 18. pii: 0268355515586097. [Epub ahead of print] PubMed PMID: 25991692. 2: Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronised purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomised trial. Int Angiol. 2015 May 14. [Epub ahead of print] PubMed PMID: 25972136. 3: Mosti G, De Maeseneer M, Cavezzi A, Parsi K, Morrison N, Nelzen O, Rabe E, Partsch H, Caggiati A, Simka M, Obermayer A, Malouf M, Flour M, Maleti O, Perrin M, Reina L, Kalodiki E, Mannello F, Rerkasem K, Cornu-Thenard A, Chi YW, Soloviy M, Bottini O, Mendyk N, Tessari L, Varghese R, Etcheverry R, Pannier F, Lugli M, Carvallo Lantz AJ, Zamboni P, Zuolo M, Godoy MF, Godoy JM, Link DP, Junger M, Scuderi A. Society for Vascular Surgery and American Venous Forum Guidelines on the management of venous leg ulcers: the point of view of the International Union of Phlebology. Int Angiol. 2015 Jun;34(3):202-18. Epub 2015 Apr 21. PubMed PMID: 25896614. 4: Pannier F, Rabe E. Progression in venous pathology. Phlebology. 2015 Mar;30(1 Suppl):95-7. doi: 10.1177/0268355514568847. Review. PubMed PMID: 25729075. 5: Rabe E, Pannier F. Embolization is not essential in the treatment of leg varices due to pelvic venous insufficiency.
    [Show full text]
  • Hemorrhoids (1 of 8)
    Hemorrhoids (1 of 8) 1 Patient presents w/ symptoms of hemorrhoids 2 DIAGNOSIS No ALTERNATIVE Hemorrhoids confi rmed & other DIAGNOSIS causes of rectal bleeding excluded? Yes Internal or external External TREATMENT hemorrhoids? hemorrhoids See page 3 Internal hemorrhoids 3 GRADE HEMORRHOIDS A Dietary modifi cation & supportive measures B Pharmacological therapy Grade I - II Grade III Grade IV Yes Response to C Ablative offi ce procedures therapy? D Surgical hemorrhoidectomy CONTINUE No TREATMENT C Ablative offi ce procedures Yes Response to No D Surgical hemorrhoidectomy ©therapy? MIMS B1 © MIMS 2019 Hemorrhoids (2 of 8) 1 SYMPTOMS ATTRIBUTED TO HEMORRHOIDS • Rectal bleeding - Most common presenting symptom - Bright red blood which may drip or squirt into the toilet bowl or scanty amounts may be seen on toilet tissue • Discomfort due to rectal protrusion or lump • Anal pain • HEMORRHOIDS Anal itching 2 DIAGNOSIS Medical History • Assess nature, duration & severity of symptoms - Ask about bleeding, its amount & frequency - Ask about presence of prolapsing tissue, its timing & reproducibility • Elicit possible risk factors for development of hemorrhoidal symptoms - Low-fi ber diets cause small-caliber stools, resulting in straining during defecation & engorgement of hemorrhoids - Prolonged sitting on a toilet which may cause a problem in the venous return in the perianal area - Pregnancy - Advanced age • Th e signs & symptoms of hemorrhoids are not specifi c to the disease, so care must be taken to avoid missing other causes of pathology • Obtain
    [Show full text]
  • PHARMACEUTICAL Antibiotics and Antibacterial
    PHARMACEUTICAL Antibiotics and Antibacterial Active Ingredient Form Strength Pack Type Packing Style Amoxicillin Sodium Dry Powder Injections 250mg, 500mg, 1000 mg Vial 1's Amoxicillin Suspension 125mg/5ml, 250mg/5ml Bottle 30ml, 60ml Amoxicillin Dispersible Tablet 125mg, 250mg Strip 10's Amoxicillin Trihydrate Tablet 1000mg Blister 10's Amoxicillin + Clavulanate Potassium Injection 500mg + 100mg, 1g + 200mg Vial 10ml, 20ml Amoxicillin + Clavulanate Potassium Suspension 200mg + 28.5mg Bottle 30ml Amoxicillin + clavulanic Acid Tablets 250mg + 125mg, 500mg + 125mg Strip , Alu-Alu 6's, 10's Amoxicillin + Cloxacillin Capsules 250mg + 250mg, 500mg + 500mg Blister 10's Amoxicillin + Cloxacillin Dry Powder Injections 250mg + 250mg Vial 1's Amoxiciilin + Cloxacillin + Lactic Acid Tablet 250 mg + 250 mg + 60 million Tablet 10's Bacillus Spores, 250 + 250 + 120 million Spores Amoxicillin + Flucloxacillin Capsules 250mg + 250mg Strip 10's Azithromycin Tablets 250mg, 500mg Blister 6's, 3's Azithromycin + Fluconazole + Secnidazole Tablet 1gm + 150mg + 1gm Strip 1 + 1 + 2 Betamethasone Valerate + Neomycin Cream 0.1% + 0.5% Tube 10g Sulphate Beclomethasone + Phenylephrine Hcl + Cream 0.025% + 0.10% + 2.5% + 0.1% Tube 10g Lignocaine Hcl + Chlorocresol Betamethasone Valerate Lotion 0.10% Bottle 30ml Betamethasone Injection 4mg/ml Ampoule 1ml Bethamethasone Opthalmic Solution 0.1% w/v Bottle 5ml Betamethasone Valerate Cream 0.1%w/w Tube 15 g Bethamethasone + Gentamicin Cream 0.1% + 0.05% Tube 10 g Betamethasone Sodium Phosphate Tablet 0.5mg Blister 10s
    [Show full text]
  • Download This Issue
    UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Contents Foreword 83 UIP Chapter Meeting August 25th -27th 2019, Krakow – Poland 85 Charing Cross International Symposium - Vascular & Endovascular Challenges Update April 15th-18th 2019, London – UK 191 81 Vol 26. No. 3. 2019 Medical Reporters’ Academy The reports from the UIP chapter meeting and Charing cross international symposium were prepared by the following members of the Medical Reporters’ Academy: Roman BREDIKHIN (Russia) Kirill LOBASTOV (Russia) Daniela MASTROIACOVO (Italy) Mustafa SIRLAK (Turkey) Stanislava TZANEVA (Austria) and chaired by: Andrew NICOLAIDES (Cyprus) 82 UIP Chapter Meeting - August 25th -27th 2019, Krakow – Poland Foreword The Medical Reporters’ Academy was co-founded in 1994 as a joint initiative by clinical and research venous disease specialists and Servier; with the main objective to develop an international group of young specialists with a core interest in venous disease drawn from various fields including dermatology, vascular surgery, angiology and/or phlebology. Each year the Medical Reporters’ Academy members are invited by Servier, to cover one of the most important international congresses for venous disease specialists. This year, the UIP Chapter Meeting, which was held in Krakow, Poland on August 25th- 27th, 2019 and the Charing Cross International Symposium: Vascular & Endovascular Challenges Update which was held in London, United Kingdom on April 15th - 18th, 2019 were selected because these congresses involved renowned international and national venous experts and young health care professionals providing a great opportunity to exchange ideas, explore strategies for vein care and discuss the latest trends & innovations in the field. Together with Andrew Nicolaides, the chairman of the group, the academy members explored the program of the congress, selected the events and presentations likely to present breakthroughs or new findings to attend, and wrote short reports.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Medicines and Related Substances Act No. 101 of 1965
    MEDICINES AND RELATED SUBSTANCES ACT NO. 101 OF 1965 [View Regulation] [ASSENTED TO 19 JUNE, 1965] [DATE OF COMMENCEMENT: 1 APRIL, 1966] (Afrikaans text signed by the State President) This Act was published in Government Gazette 40869 dated 26 May, 2017. as amended by Drugs Control Amendment Act, No. 29 of 1968 Drugs Control Amendment Act, No. 88 of 1970 Drugs Laws Amendment Act, No. 95 of 1971 Drugs Control Amendment Act, No. 65 of 1974 Medicines and Related Substances Control Amendment Act, No. 19 of 1976 Health Laws Amendment Act, No. 36 of 1977 Medicines and Related Substances Control Amendment Act, No. 17 of 1979 Medicines and Related Substances Control Amendment Act, No. 20 of 1981 Transfer of Powers and Duties of the State President Act, No. 97 of 1986 [with effect from 3 October, 1986] Businesses Act, No. 71 of 1991 [with effect from 24 May, 1991] Medicines and Related Substances Control Amendment Act, No. 94 of 1991 General Law Amendment Act, No. 49 of 1996 [with effect from 4 October, 1996] Abolition of Restrictions on the Jurisdiction of Courts Act, No. 88 of 1996 [with effect from 22 November, 1996] Medicines and Related Substances Control Amendment Act, No. 90 of 1997 Medicines and Related Substances Amendment Act, No. 59 of 2002 Judicial Matters Amendment Act, No. 66 of 2008 [with effect from 17 February, 2009] Medicines and Related Substances Amendment Act No. 72 of 2008 Medicines and Related Substances Amendment Act, No. 14 of 2015 GENERAL NOTE There is a discrepancy between the English and Afrikaans texts of section 1 of Act No.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]